Explore › Finding
Finding decline
HIV-positive smokers taking efavirenz had significantly faster nicotine metabolism (higher NMR) than those not taking efavirenz in a multiple regression model, with efavirenz alone accounting for 5% unique variance in NMR.
Effect sizeb = 0.221, p = .010
ComparatorHIV-positive smokers not taking efavirenz
Effect summarydecline; b = 0.221, p = .010

Connected entities

Interventions
Efavirenz-based antiretroviral therapy
Conditions
HIV
Outcomes
Nicotine metabolite ratio
Populations
HIV-positive Patients

Source

PMC6331237
Rate of Nicotine Metabolism and Tobacco Use among Persons with HIV: Implications for Treatment and Research
Read on PMC → · View in graph →